The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

PODD

Insulet Corp.

Healthcare · Medical - Devices

Overall research band Mixed
Quality Above average
Valuation Mixed
Balance sheet Above average
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Its main products include the Omnipod platform, featuring the Omnipod 5 automated insulin delivery system with a proprietary algorithm and Bluetooth integration, the Omnipod DASH insulin management system with a smartphone-like controller, and the Omnipod Insulin Management System. Insulet also supplies pods for Amgen's Neulasta Onpro kit, a delivery system used to reduce infection risk after chemotherapy. The company sells its products to end-users through the pharmacy channel and independent distributors.

The current research profile is Mixed Setup, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC21.2%Model input; read with the evidence status and period context.
Operating margin17.5%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years25.3%Model input; read with the evidence status and period context.
FCF margin14.2%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.